CERVIX | CERVICAL SCREENING [ISSN 1804-087X]
česky | english | sitemap


PARTNERS AND EXPERT GUARANTEE
 
Czech Gynaecological and Obstetrical Society | Ministry of Health | Institute of Biostatistics and Analyses, Masaryk University
GRANT SUPPORT OF THE PROJECT
 
GlaxoSmithKline     Roche |

Other sources of information
Cervical cytology (in Czech)www.cipek.cz
Cervical cytology
 
Cancer Screening in the European Unionec.europa.eu
Cancer Screening in the European Union (2017)
[ 10,6 MB]
 
SVOD - Epidemiology of malignant tumours in the Czech Republicwww.svod.cz
Epidemiology of malignant tumours
in the Czech Republic
 
NCI Bethesda System
HPV College

 

HPV vaccine protects against cervical cancer for at least six years

The Cervarix vaccine provides protection against two types of human papillomavirus (HPV) for more than six years, US scientists have reported.


image courtesy of piyaphantawong / FreeDigitalPhotos.net

Cervarix is manufactured by GlaxoSmithKline and protects against HPV types 16 and 18, which are responsible for the majority of cases of cervical cancer.

Previous studies have shown the vaccine to be effective over a sustained period of time and the latest study, which is published in the Lancet medical journal, provides further evidence.

The report contains the final analysis of a study which originally began in 2001 and was extended to enable participants to be followed for nearly six and a half years after their vaccination.

Read the whole article at Cancer Research UK

References

  1. Clifford, G. (2009). Global access to HPV vaccination: what are we waiting for? The Lancet DOI: 10.1016/S0140-6736(09)61789-X

6.12.2009 Cancer Research UK


Back